USPTO Examiner KOSSON ROSANNE - Art Unit 1759

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19061532EXTRACTION OF ANTIMETHANOGENIC COMPOUNDSFebruary 2025June 2025Allow411YesNo
19003326COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES AND CONDITIONS INCLUDING ECZEMADecember 2024May 2025Allow401YesNo
18932631COMPOSITION FOR IMPROVING RESPIRATORY HEALTH OF COMPANION ANIMALSOctober 2024January 2025Allow200YesNo
18891931EXTRACTION OF ANTIMETHANOGENIC COMPOUNDSSeptember 2024January 2025Allow401YesNo
18889340COMPOSITION AND USE THEREOF FOR THE TREATMENT OF EQUINE GASTRIC ULCER SYNDROMESeptember 2024January 2025Allow401YesNo
18600907SOLUBILIZATE WITH CURCUMIN AND OPTIONALLY AT LEAST ONE OTHER ACTIVE SUBSTANCEMarch 2024October 2024Allow700YesNo
18439503APPARATUSES AND SYSTEMS FOR PREPARING A MEAT PRODUCTFebruary 2024October 2024Allow812YesNo
18412174BIOLOGIC ENHANCEMENT FORMULATIONJanuary 2024September 2024Allow812YesNo
18395925METHODS AND COMPOSITIONS FOR TREATING MUSCULOSKELETAL DISEASES, TREATING INFLAMMATION, AND MANAGING SYMPTOMS OF MENOPAUSEDecember 2023May 2025Allow1711YesNo
18531157Parallel Cell Processing Method and FacilityDecember 2023June 2025Allow1821YesNo
18506930Thin Film Cell Encapsulation DevicesNovember 2023June 2025Allow2002YesNo
18493979MATERIALS AND METHODS FOR INHIBITING A VIRAL INFECTION, INCLUDING A CORONAVIRUS INFECTIONOctober 2023May 2025Allow1911YesNo
18376832Carbon Capture by Algal Inoculation of Ocean Ice and/or Sea IceOctober 2023June 2025Allow2001YesNo
18376827MATERIALS AND METHODS FOR ALGAL INOCULATION TO EFFECT DIRECT CAPTURE OF CARBON DIOXIDE FROM AIROctober 2023June 2025Allow2001YesNo
18479701COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERSOctober 2023June 2025Abandon2001NoNo
18477298IMMUNOMODULATORY COMPOSITIONS COMPRISING MICROBIAL ENTITIESSeptember 2023May 2025Allow1911YesNo
18468980Placental Tissue CompositionsSeptember 2023May 2025Abandon2001NoNo
18243568METHOD FOR GUT MUCOSA PREPARATION TO ENHANCE MICROBIAL ENGRAFTMENTSeptember 2023March 2025Allow1913YesNo
18364153HUMAN AND NON-HUMAN ANIMAL USE OF MICROBIAL ANAPLEROTIC OILAugust 2023January 2025Allow1801YesNo
18361067Method to Convert Insects or Worms into Nutrient Streams and Compositions Obtained TherebyJuly 2023October 2024Allow1501YesNo
18358465MUSCLE DERIVED CELLS FOR THE TREATMENT OF URINARY TRACT PATHOLOGIES AND METHODS OF MAKING AND USING THE SAMEJuly 2023April 2025Abandon2001NoNo
18357888METHODS AND COMPOSITIONS OF BIOCONTROL OF PLANT PATHOGENSJuly 2023February 2025Allow1911YesNo
18352386THRAUSTOCHYTRIDS, FATTY ACID COMPOSITIONS, AND METHODS OF MAKING AND USES THEREOFJuly 2023May 2025Allow2211YesNo
18351286METHODS FOR TREATING POLYMICROBIAL INFECTIONSJuly 2023July 2024Allow1201YesNo
18351385METHODS FOR TREATING POLYMICROBIAL INFECTIONSJuly 2023July 2024Allow1300YesNo
18351018CORAL COMPOSITE EXTRACT, COMPOSITION INCLUDING THE SAME AND METHOD OF PRODUCING THE SAMEJuly 2023February 2024Allow700YesNo
18212059BIOPOLYMER COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF GASTRIC ULCERSJune 2023October 2024Allow1621YesNo
18337884METHOD FOR TESTING DRUG RESPONSE OF CARDIOMYOCYTESJune 2023February 2025Abandon2001NoNo
18210113GLUCOSYLATED STEVIOL GLYCOSIDE AS A FLAVOR MODIFIERJune 2023December 2024Allow1811YesNo
18331085TERPENE-BASED COMPOSITIONS, METHODS OF PREPARATIONS AND USES THEREOFJune 2023February 2025Abandon2101NoNo
18203306MATERNAL SUPPLEMENTMay 2023April 2024Allow1001YesNo
18142392COMPOSITIONS AND METHODS FOR DIGESTIVE HEALTH IN AN ANIMALMay 2023April 2024Allow1211YesNo
18306316Probiotic Formulations for Improving Athletic PerformanceApril 2023February 2025Abandon2211NoNo
18305361Highly Scalable and Practical Method for Immobilizing and Efficiently Culturing Algae for Various ApplicationsApril 2023July 2023Allow301YesNo
18304264IMMUNOMODULATORY COMPOSITIONS COMPRISING MICROBIAL ENTITIESApril 2023August 2023Allow401YesNo
18296774COMPOSITION COMPRISING AN ALGAL PROTEOGLYCAN EXTRACT AND USE THEREOFApril 2023September 2024Allow1731YesNo
18130118ORAL COMPOSITION COMPRISING LACTIC ACID BACTERIA FOR REGULATING IMMUNE RESPONSES AND METHODS RELATED THERETOApril 2023July 2024Allow1601YesNo
18129335METHOD OF SYNERGETIC MINIMIZATION OF NEGATIVE IMPACT CAUSED BY FLIGHTS ON HUMAN HEALTHMarch 2023February 2024Allow1001YesNo
18186095BIOSENSORS FOR DETECTING AND/OR NEUTRALIZING BIOAVAILABLE URANIUM AND RELATED U-SENSITIVE GENETIC MOLECULAR COMPONENTS, GENE CASSETTES, VECTORS, GENETIC CIRCUITS, COMPOSITIONS, METHODS AND SYSTEMSMarch 2023January 2025Allow2212YesNo
18181495METHODS AND COMPOSITIONS FOR TREATING MUSCULOSKELETAL DISEASES, TREATING INFLAMMATION, AND MANAGING SYMPTOMS OF MENOPAUSEMarch 2023November 2023Allow801YesNo
18178966CHOLESTEROL REDUCING COMPOSITIONS AND METHODS OF USE THEREOFMarch 2023July 2024Allow1611YesNo
18019979Compositions and Methods for Treating Viral InfectionFebruary 2023October 2023Allow801YesNo
18162774Variable Diameter BioreactorsFebruary 2023October 2024Allow2112YesNo
18160950COMPOSITIONS AND METHODS FOR TREATMENT OF SARS-COV-2January 2023March 2024Allow1322YesNo
18146706NOVEL BIFIDOBACTERIUM BACTERIA AND COMPOSITION INCLUDING NOVEL BIFIDOBACTERIUM BACTERIADecember 2022August 2024Allow1921YesNo
18079155NUTRITIONAL COMPOSITIONDecember 2022March 2024Allow1511YesNo
18063267THERAPEUTIC USE OF ENGINEERED POSTBIOTICS COMPRISING BACTERIOCINS AND/OR ENDOLYSINSDecember 2022July 2023Allow801YesNo
18063447Methods and reagents for treating diabetesDecember 2022August 2024Abandon2111NoNo
18074837PLATED HEPATOCYTES AND PREPARATION AND USES THEREOFDecember 2022November 2024Allow2322YesNo
17979346INDIGENOUS AND IMPROVED BACTERIALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMSNovember 2022February 2024Allow1601YesNo
17967886COPPER CHELATION THERAPEUTICSOctober 2022July 2024Allow2102YesNo
17957524MINT MASK AND METHODS OF USE THEREOFSeptember 2022June 2024Abandon2001NoNo
17915306PHARMACEUTICAL COMPOSITION COMPRISING NEW LACTOBACILLUS PLANTARUM KC3 STRAIN AND LEONURUS JAPONICUS EXTRACT AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING RESPIRATORY DISEASE AND USE THEREOFSeptember 2022April 2025Allow3001YesNo
17945125Blood Plasma ProductSeptember 2022December 2023Allow1512YesNo
17899752FRUIT AND VEGETABLE POMACE COMPOSITION AND USE AS BLOOD GLUCOSE MODULATOR AND ANTI-DIABETIC AGENTAugust 2022April 2024Allow1911YesNo
17821134DEXTROMETHORPHAN AND GUAIFENESIN SYRUP FORMULATION OR SUSPENSIONAugust 2022October 2023Allow1401YesNo
17821138DIPHENHYDRAMINE SYRUP FORMULATION OR SUSPENSIONAugust 2022October 2024Abandon2611NoNo
17819050COMPOSITIONS COMPRISING PROPIONIBACTERIUM ACNES BACTERIOPHAGES FOR TREATING ACNEAugust 2022November 2023Allow1512YesNo
17818772HUMAN AND NON-HUMAN ANIMAL USE OF MICROBIAL ANAPLEROTIC OILAugust 2022June 2023Allow1010YesNo
17818749COMPOSITIONS AND METHODS FOR TREATING SKINAugust 2022November 2023Allow1510YesNo
17816515METHOD OF TRANSPORTING MESENCHYMAL STEM CELLS BY MEANS OF A TRANSPORTING SOLUTION AND A METHOD OF ADMINISTERING STEM CELLS TO WOUNDSAugust 2022January 2024Allow1811YesNo
17812873INHIBITION OF ENTERIC INFECTION THROUGH THE MODULATION OF MICROBIOTAJuly 2022September 2023Allow1401YesNo
17828201Compositions and Methods for Diagnosing Susceptibility to Autism Spectrum Disorder (ASD), Reducing the Likelihood of Developing ASD, and/or Treating ASDMay 2022August 2024Allow2612YesNo
17756570COMPOSITIONS AND METHODS WITH A PROBIOTIC AND A NUTRIENT AND/OR MINERAL FOR THE PREVENTION OR TREATMENT OF MASTITISMay 2022April 2025Abandon3501NoNo
17755837FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKEMay 2022June 2025Allow3701YesNo
17727934CYANOBACTERIAL HOSTS AND METHODS FOR PRODUCING CHEMICALSApril 2022January 2024Allow2011YesNo
17724386METHOD FOR PRODUCING MARINE ALGAE-DERIVED AGAROTRIOSE, AND USE THEREOF AS PREBIOTICApril 2022September 2023Allow1701YesNo
17714955NOVEL LACTIC ACID BACTERIA AND USE THEREOFApril 2022December 2023Allow2111YesNo
17762014BIFIDOBACTERIUM BREVE 207-1 AND USE THEREOFMarch 2022June 2023Allow1511YesNo
17685568SHEET-SHAPED CELL CULTURE PREPARATION DEVICEMarch 2022April 2025Allow3811YesNo
17684323COMPOSITION FOR USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDERMarch 2022January 2024Allow2212YesNo
17682051METHODS FOR INCREASING GROWTH OF BENEFICIAL BACTERIA IN THE GASTROINTESTINAL TRACTFebruary 2022August 2023Allow1801YesNo
17671959METHOD AND COMPOSITION FOR AMELIORATING DRUG SEEKING BEHAVIORFebruary 2022December 2023Allow2211YesNo
17632211METHODS OF IMPROVING PROTEIN PRODUCTIVITY IN FED-BATCH CELL CULTURESFebruary 2022May 2025Abandon4001NoNo
17558043Thin Film Cell Encapsulation DevicesDecember 2021January 2024Abandon2501NoNo
17544808SOLUBILIZATE WITH CURCUMIN AND OPTIONALLY AT LEAST ONE OTHER ACTIVE SUBSTANCEDecember 2021November 2023Allow2311YesNo
17616591METHOD FOR GUT MUCOSA PREPARATION TO ENHANCE MICROBIAL ENGRAFTMENTDecember 2021August 2023Allow2003YesNo
17615419HUMAN DISEASED AND NORMAL KIDNEY EPITHELIAL CELL CULTURES AND USES THEREOFNovember 2021April 2025Abandon4101NoNo
17530114COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERSNovember 2021December 2023Abandon2501NoNo
17611782PHOTOACTIVATED BLOOD PRODUCTS AND METHODS AND APPARATUS FOR FABRICATION AND USE OF SAMENovember 2021September 2024Allow3411YesNo
17526663METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURENovember 2021May 2024Allow3003YesNo
17604040USE OF EXTRACT FROM RABBIT SKIN INFLAMED BY VACCINIA VIRUS IN TREATING HEMATOPOIETIC SYSTEM DAMAGENovember 2021May 2024Allow3101YesNo
17454692METHOD FOR PURIFYING NEURAL CREST CELLS OR CORNEAL EPITHELIAL CELLSNovember 2021November 2024Allow3601YesNo
17610485PLURIPOTENT CELL AGGREGATES AND USE THEREOFNovember 2021November 2024Allow3601YesNo
17521529Weight Management CompositionNovember 2021March 2025Allow4011YesNo
17609460PHARMACEUTICAL COMPOSITION COMPRISING PERIODONTAL TISSUE-DERIVED PLURIPOTENT STEM CELLS FOR PREVENTION OR TREATMENT OF MALE INFERTILITYNovember 2021November 2024Allow3601YesNo
17513901METHOD AND A DIETARY COMPOSITION ON REGULATION, TREATMENT, AND PREVENTION OF OBESITYOctober 2021August 2023Allow2111YesNo
17607389PHARMACEUTICAL COMPOSITION FOR TREATING SEPSIS OR SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENTOctober 2021December 2024Abandon3802NoNo
17511228GENERATION OF FUNCTIONAL AND PATIENT-SPECIFIC THYMIC TISSUE FROM INDUCED PLURIPOTENT STEM CELLSOctober 2021April 2025Allow4202YesNo
17504668PACKAGING FOR WET TISSUE STORAGEOctober 2021August 2024Allow3401YesNo
17503583ANIMAL TREATMENT PASTES AND OINTMENTS AND METHODS OF USING SAMEOctober 2021July 2023Allow2101YesNo
17604541PROCESS FOR OBTAINING BIOLOGICALLY ACTIVE COMPOSITIONS FROM EMU OIL, ANTIINFLAMMATORY AND ANTI-IRRITANT PHARMACEUTICAL COMPOSITION, AND SKIN REGENERATIVE PHARMACEUTICAL COMPOSITIONOctober 2021April 2024Allow3001YesNo
17603195EARLY LIFE NUTRITIONOctober 2021September 2024Allow3501YesNo
17602421METHOD FOR PRODUCING BIOLOGICAL TISSUE-LIKE STRUCTUREOctober 2021November 2024Allow3811YesNo
17448684EYEDROP APPLICABLE TO LIMBAL STEM CELL DEFICIENCY AND PREPARATIONSeptember 2021April 2024Allow3101YesNo
17479597METHOD OF MAKING STEVIOL GLYCOSIDESSeptember 2021September 2024Abandon3520NoNo
17468485SPORE-BASED PROBIOTIC COMPOSITION FOR MODULATION OF DERMAL AND SUB-DERMAL PROPERTIESSeptember 2021June 2023Allow2101YesNo
17435437INDUCTION METHOD FOR MACROPHAGE, ANTI-INFLAMMATORY MACROPHAGE-INDUCING AGENT, AND PHARMACEUTICAL COMPOSITIONSeptember 2021March 2025Allow4222YesNo
17434925ACOUSTIC EXTRACELLULAR MATRIX HYDROGELS AND THEIR USEAugust 2021October 2024Allow3811YesNo
17434417USE OF MESENCHYMAL STEM CELLS IN TREATING IMMUNE-RELATED DISEASESAugust 2021November 2024Allow3831YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOSSON, ROSANNE.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
1
(25.0%)
Not Allowed After Appeal Filing
3
(75.0%)
Filing Benefit Percentile
30.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KOSSON, ROSANNE - Prosecution Strategy Guide

Executive Summary

Examiner KOSSON, ROSANNE works in Art Unit 1759 and has examined 193 patent applications in our dataset. With an allowance rate of 83.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner KOSSON, ROSANNE's allowance rate of 83.9% places them in the 53% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by KOSSON, ROSANNE receive 0.82 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KOSSON, ROSANNE is 28 months. This places the examiner in the 50% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +97.0% benefit to allowance rate for applications examined by KOSSON, ROSANNE. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 57.7% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 3% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 34.0% are granted (fully or in part). This grant rate is in the 28% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 60% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.